Sadagopal Shanmugalakshmi, Braunstein Miriam, Hager Cynthia C, Wei Jie, Daniel Alexandria K, Bochan Markian R, Crozier Ian, Smith Nathaniel E, Gates Hiriam O, Barnett Louise, Van Kaer Luc, Price James O, Blackwell Timothy S, Kalams Spyros A, Kernodle Douglas S
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
PLoS One. 2009;4(5):e5531. doi: 10.1371/journal.pone.0005531. Epub 2009 May 13.
In early clinical studies, the live tuberculosis vaccine Mycobacterium bovis BCG exhibited 80% protective efficacy against pulmonary tuberculosis (TB). Although BCG still exhibits reliable protection against TB meningitis and miliary TB in early childhood it has become less reliable in protecting against pulmonary TB. During decades of in vitro cultivation BCG not only lost some genes due to deletions of regions of the chromosome but also underwent gene duplication and other mutations resulting in increased antioxidant production.
METHODOLOGY/PRINCIPAL FINDINGS: To determine whether microbial antioxidants influence vaccine immunogenicity, we eliminated duplicated alleles encoding the oxidative stress sigma factor SigH in BCG Tice and reduced the activity and secretion of iron co-factored superoxide dismutase. We then used assays of gene expression and flow cytometry with intracellular cytokine staining to compare BCG-specific immune responses in mice after vaccination with BCG Tice or the modified BCG vaccine. Compared to BCG, the modified vaccine induced greater IL-12p40, RANTES, and IL-21 mRNA in the spleens of mice at three days post-immunization, more cytokine-producing CD8+ lymphocytes at the peak of the primary immune response, and more IL-2-producing CD4+ lymphocytes during the memory phase. The modified vaccine also induced stronger secondary CD4+ lymphocyte responses and greater clearance of challenge bacilli.
CONCLUSIONS/SIGNIFICANCE: We conclude that antioxidants produced by BCG suppress host immune responses. These findings challenge the hypothesis that the failure of extensively cultivated BCG vaccines to prevent pulmonary tuberculosis is due to over-attenuation and suggest instead a new model in which BCG evolved to produce more immunity-suppressing antioxidants. By targeting these antioxidants it may be possible to restore BCG's ability to protect against pulmonary TB.
在早期临床研究中,活结核疫苗牛分枝杆菌卡介苗(BCG)对肺结核(TB)显示出80%的保护效力。尽管BCG在幼儿期对结核性脑膜炎和粟粒性结核仍表现出可靠的保护作用,但在预防肺结核方面已变得不太可靠。在数十年的体外培养过程中,BCG不仅由于染色体区域的缺失而丢失了一些基因,还经历了基因复制和其他突变,导致抗氧化剂产量增加。
方法/主要发现:为了确定微生物抗氧化剂是否影响疫苗免疫原性,我们消除了BCG Tice中编码氧化应激σ因子SigH的重复等位基因,并降低了铁辅助超氧化物歧化酶的活性和分泌。然后,我们使用基因表达测定和细胞内细胞因子染色的流式细胞术,比较用BCG Tice或改良BCG疫苗接种后小鼠体内的BCG特异性免疫反应。与BCG相比,改良疫苗在免疫后三天诱导小鼠脾脏中产生更多的IL-12p40、RANTES和IL-21 mRNA,在初次免疫反应高峰期产生更多产生细胞因子的CD8+淋巴细胞,在记忆期产生更多产生IL-2的CD4+淋巴细胞。改良疫苗还诱导更强的二次CD4+淋巴细胞反应和更大程度地清除攻击杆菌。
结论/意义:我们得出结论,BCG产生的抗氧化剂会抑制宿主免疫反应。这些发现挑战了广泛培养的BCG疫苗未能预防肺结核是由于过度减毒的假设,而是提出了一个新模型,即BCG进化为产生更多抑制免疫的抗氧化剂。通过靶向这些抗氧化剂,有可能恢复BCG预防肺结核的能力。